Adlai Nortye Reports H1 2025 Results & Pipeline Update
Ticker: ANL · Form: 6-K · Filed: Dec 29, 2025 · CIK: 1944552
Sentiment: neutral
Topics: pipeline-update, financial-results, biotech
TL;DR
Adlai Nortye dropped H1 2025 numbers and is touting its new drug AN8025's preclinical success.
AI Summary
Adlai Nortye Ltd. reported its unaudited first half 2025 financial results and provided an update on its operational progress. The company highlighted its pipeline, specifically mentioning AN8025, a next-generation tri-specific antibody fusion protein designed to modulate T cell and antigen-presenting cell functions. Preclinical studies for AN8025 have shown enhanced T cell and APC functions.
Why It Matters
This filing provides investors with an update on Adlai Nortye's financial performance and the development status of its promising drug candidate, AN8025, which could impact future revenue streams.
Risk Assessment
Risk Level: medium — The filing discusses financial results and pipeline progress, which are standard for a 6-K, but the success of the drug candidate AN8025 is still in early stages and carries inherent development risks.
Key Players & Entities
- Adlai Nortye Ltd. (company) — Filer of the report
- AN8025 (drug_candidate) — Next-generation tri-specific antibody fusion protein
FAQ
What are the unaudited first half 2025 financial results for Adlai Nortye Ltd.?
The filing states that Adlai Nortye Ltd. reported its unaudited first half 2025 financial results, but the specific figures are not detailed within the provided text.
What is AN8025 and what is its intended function?
AN8025 is a next-generation tri-specific antibody fusion protein designed to modulate T cell and antigen-presenting cell (APC) functions.
What has been demonstrated in preclinical studies for AN8025?
Preclinical studies have demonstrated that AN8025 enhances both the quantity and function of T cells and antigen-presenting cells (APCs).
What type of company is Adlai Nortye Ltd. based on its SIC code?
Adlai Nortye Ltd. is classified under Pharmaceutical Preparations (SIC code 2834).
What is the filing form and period of report?
The filing is a Form 6-K, a Report of Foreign Private Issuer, for the month of December 2025, with the Conformed Period of Report being 20251229.
Filing Stats: 2,162 words · 9 min read · ~7 pages · Grade level 16.3 · Accepted 2025-12-29 06:03:48
Key Financial Figures
- $44.1 million — 25, cash and cash equivalents totaled US$44.1 million compared to US$60.9 million on December
- $60.9 million — s totaled US$44.1 million compared to US$60.9 million on December 31, 2024. As of June 30, 20
- $18.2 million — une 30, 2025, restricted cash totaled US$18.2 million compared to nil on December 31, 2024.
- $15.1 m — he six months ended June 30, 2025 was US$15.1 million, compared to US$28.4 million for
- $28.4 million — 2025 was US$15.1 million, compared to US$28.4 million for the six months ended June 30, 2024.
- $26.0 million — ment expenses decreased by 41.4% from US$26.0 million for the six months ended June 30, 2024
- $15.2 million — the six months ended June 30, 2024 to US$15.2 million for the six months ended June 30, 2025.
- $4.7 million — tive expenses decreased by 13.8% from US$4.7 million for the six months ended June 30, 2024
- $4.1 million — the six months ended June 30, 2024 to US$4.1 million for the six months ended June 30, 2025,
- $2.6 million — s. Other gains decreased by 45% from US$2.6 million for the six months ended June 30, 2024
- $1.4 million — the six months ended June 30, 2024 to US$1.4 million for the six months ended June 30, 2025,
- $27.7 million — June 30, 2025 decreased by 33.6% from US$27.7 million for the six months ended June 30, 2024
- $18.3 million — the six months ended June 30, 2024 to US$18.3 million for the six months ended June 30, 2025.
- $0.0001 — Class A Ordinary shares (par value of $0.0001 per share; 93,710,803 shares outstandin
Filing Documents
- ea0270767-6k_adlai.htm (6-K) — 94KB
- image_001.jpg (GRAPHIC) — 183KB
- 0001213900-25-125572.txt ( ) — 348KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Adlai Nortye Ltd. By: /s/ Yang Lu Name: Yang Lu Title: Chief Executive Officer and Chairman of Board of Directors Date: December 29, 2025 8